Evidence map›Paper›PMID 39736685›Full record

ArticleCritical care (London, England)2024

High rates of cefiderocol plasma target attainment: results of a retrospective cohort study in 31 critically ill ICU patients.

Hans Theodor Naumann, Rainer Höhl, Martina Kinzig, Sophie Salat, Vanessa Bartsch, Fritz Sörgel, Ralph Bertram, Joerg Steinmann, Therapeutic Drug Monitoring study group

Erratum issuedAbstract readLetter
In one paragraph

Article in Critical care (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Cefiderocol for Treatment of Ventriculitis (4MRGNAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Hans Theodor Naumann *Institute of Clinical Microbiology, Infectious Diseases and Infection Control, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.ORCID http://orcid.org/0000-0003-2983-0887
Rainer Höhl *Institute of Clinical Microbiology, Infectious Diseases and Infection Control, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.ORCID http://orcid.org/0000-0001-6681-9703
Martina KinzigInstitute for Biomedical and Pharmaceutical Research, Nuremberg-Heroldsberg, Germany.ORCID http://orcid.org/0000-0001-6381-8991
Sophie SalatStudy Program in Human Medicine, Paracelsus Medical University, Nuremberg, Germany.
Vanessa BartschStudy Program in Human Medicine, Paracelsus Medical University, Nuremberg, Germany.ORCID http://orcid.org/0000-0001-6029-2103
Fritz SörgelInstitute for Biomedical and Pharmaceutical Research, Nuremberg-Heroldsberg, Germany.ORCID http://orcid.org/0009-0004-7140-2581
Ralph BertramInstitute of Clinical Microbiology, Infectious Diseases and Infection Control, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany. ralph.bertram@klinikum-nuernberg.de.ORCID http://orcid.org/0000-0003-0654-6381
Joerg SteinmannInstitute of Clinical Microbiology, Infectious Diseases and Infection Control, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany. joerg.steinmann@klinikum-nuernberg.de.ORCID http://orcid.org/0000-0002-3181-3667
Therapeutic Drug Monitoring study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AntibioticsAntiinfectivesCefiderocolPharmacodynamicsPharmacokineticsTherapeutic drug monitoring

Identifiers

PMID39736685
PMCPMC11684300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.